On the Diagnosing Dx podcast, Helio Genomics CEO Bharat Tewarie, MD, MBA, makes the case for why AI-powered multiomics is poised to replace ultrasound in liver cancer screening — and why earlier detection only counts if patients can actually access it.
About the episode
In this episode of Diagnosing Dx — hosted by Elevra Consulting — Bharat Tewarie, MD, MBA, CEO of Helio Genomics, joins the show. Since taking the helm in July 2025, he brings decades of global healthcare leadership across pharma, biotech, diagnostics, and digital health to the company’s mission.
The conversation digs into why liver cancer surveillance still leans so heavily on outdated imaging, why so many high-risk patients fall through the cracks, and how Helio is working to change that with a more scalable, blood-based approach to early detection. Along the way, Tewarie weighs the limits of ultrasound, the promise of AI-powered multiomics, and a point he keeps returning to: early detection only matters if patients can actually access it.
Drawing on his clinical and commercial background, he also explains how Helio thinks about workflow design, physician adoption, partnerships, and the infrastructure it takes to move from scientific validation to real clinical impact — a practical look at liver cancer, access, commercialization, and what turns better diagnostics into better outcomes.
Key takeaways
- Why liver cancer surveillance still leaves too many high-risk patients undetected
- How AI-powered multiomics could improve early liver cancer detection
- Why access and workflow matter just as much as scientific performance
- How partnerships can accelerate commercialization and patient reach
- What Helio Genomics is building beyond HelioLiver as it expands its platform
Also available on Spotify and Apple Podcasts.